5-Hydroxytryptophan

From Wikipedia, the free encyclopedia

  (Redirected from 5-HTP)
Jump to: navigation, search
5-Hydroxytryptophan
IUPAC name
Identifiers
CAS number [56-69-9]
PubChem 144
MeSH 5-Hydroxytryptophan
SMILES
ChemSpider ID 388413
Properties
Molecular formula C11H12N2O3
Molar mass 220.23 g/mol
Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)

Infobox references

5-Hydroxytryptophan or 5-HTP is a naturally occurring amino acid, a precursor to the neurotransmitter serotonin and an intermediate in tryptophan metabolism. It is marketed in the United States and other countries as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid. However, according to a 2001 meta-analysis, insufficient high quality research has been done to establish that it is effective.[1] Because it is naturally occurring it has not been sought to be approved as a drug in any country.

Contents

[edit] Metabolism

5-Hydroxytryptophan is decarboxylated to serotonin (5-hydroxytryptamine or 5-HT) by the enzyme aromatic-L-amino-acid decarboxylase with the help of Vitamin B6.[2]

This reaction occurs both in nervous tissue and in the liver.[3] 5-HTP crosses the blood-brain barrier, while 5-HT does not. Excess 5-HTP, especially when administered with Vitamin B6, is thought to be metabolized and excreted.[4][5]

[edit] Pharmacology

The psychoactive action of 5-HTP is thought to derive from its effect on serotonin synthesis in central nervous system tissue. It is believed that an artificially high supply of 5-HTP causes the brain's serotonin-producing neurons to increase production. Increased serotonin production then leads to increased serotonin release and generally improved mood.

Research shows that co-administration with carbidopa greatly increases plasma 5-HTP levels.[6] However, several studies have reported that 5-HTP is effective even without a peripheral decarboxylase inhibitor (e.g. carbidopa).[7][8] Other studies have indicated the risk of a scleroderma-like condition resulting from the combination of 5-HTP and carbidopa.[9]

[edit] As a therapeutic supplement

5-HTP, which is found in minute amounts in certain foods like cheese and the white meat of poultry,[citation needed] is often sold as an over-the-counter therapeutic supplement. In this case, it is usually sourced from the seeds of Griffonia simplicifolia. 5-HTP in supplement form is typically sold in 50 mg or 100 mg gelatin or vegetarian capsules.

[edit] Research

5-HTP has been studied and shown to be of benefit in the following conditions: Primary fibromyalgia syndrome, Friedreich's ataxia, LSD-induced psychosis, chronic headaches (primary or otherwise), depression, binge eating associated with obesity, and insomnia.


J Int Med Res. 1990 May-Jun;18(3):201-9. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. Arch Neurol. 1995 May;52(5):456-60. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Am J Psychiatry. 1983 Apr;140(4):456-8. L-5-hydroxytryptophan for LSD-induced psychosis. J Neurosurg Sci. 1985 Jul-Sep;29(3):239-48. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. Altern Med Rev. 1998 Aug;3(4):271-80.5-Hydroxytryptophan: a clinically-effective serotonin precursor.

A recent (2001) meta-analysis found that of 108 studies on 5-HTP published between 1966 and 2000, only two met the authors' quality standards for inclusion. The two studies that were deemed of sufficient quality did not deal with 5-HTP exclusively, instead combining results for 5-HTP and tryptophan, so the results may not be completely applicable for 5-HTP alone. While the combined analysis of the two 5-HTP and tryptophan studies showed significant effectiveness over placebo in treating depression, the authors state that overall "the evidence was of insufficient quality to be conclusive." They also state that "because alternative antidepressants exist which have been proven to be effective and safe the clinical usefulness of 5-HTP and tryptophan is limited at present."[10]

Metabolic pathway from tryptophan to serotonin.

[edit] Possible risks or side effects

Because 5-HTP has not been thoroughly studied in a clinical setting, possible side effects and interactions with other drugs are not well known, however it has been sold since the 1990's in the US otc without any serious problems reported.

Due to the conversion of 5-HTP into serotonin by the liver, there is a possible yet unproven risk of heart valve disease from serotonin's effect on the heart.[11][12][original research?]

Direct and indirect evidence for possible yet unproven risks and side effects associated with 5-HTP when overdosed:

In people:


[edit] See also

[edit] References

  1. ^ Shaw K, Turner J, Del Mar C (2001). "Tryptophan and 5-hydroxytryptophan for depression". Cochrane Database Syst Rev (3): CD003198. doi:10.1002/14651858.CD003198. PMID 11687048. 
  2. ^ Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M (1982). "Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats". Jpn. J. Pharmacol. 32 (5): 803–11. doi:10.1254/jjp.32.803. PMID 6983619. 
  3. ^ Bouchard S, Bousquet C, Roberge AG. Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat. J Neurochem. 1981 Sep;37(3):781-7. PMID 6974228
  4. ^ Bouchard S, Roberge AG (1979). "Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat". Can. J. Biochem. 57 (7): 1014–8. PMID 39668. 
  5. ^ Amamoto T, Sarai K (1976). "On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression". Hiroshima J. Med. Sci. 25 (2-3): 135–40. PMID 1088369. 
  6. ^ Magnussen I, Jensen TS, Rand JH, Van Woert MH (1981). "Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man". Acta pharmacologica et toxicologica 49 (3): 184–9. PMID 6175178. 
  7. ^ Birdsall TC (1998). "5-Hydroxytryptophan: a clinically-effective serotonin precursor". Alternative medicine review : a journal of clinical therapeutic 3 (4): 271–80. PMID 9727088. 
  8. ^ VRP's Article on 5-HTP Safety
  9. ^ Sternberg EM, Van Woert MH, Young SN, et al. (1980). "Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa". N. Engl. J. Med. 303 (14): 782–7. PMID 6997735. 
  10. ^ Shaw K, Turner J, Del Mar C (2001). "Tryptophan and 5-hydroxytryptophan for depression". Cochrane Database Syst Rev (3): CD003198. doi:10.1002/14651858.CD003198. PMID 11687048. 
  11. ^ a b Gustafsson BI, Tømmerås K, Nordrum I, Loennechen JP, Brunsvik A, Solligård E, Fossmark R, Bakke I, Syversen U, Waldum H (March 2005). "Long-term serotonin administration induces heart valve disease in rats". Circulation 111 (12): 1517–22. doi:10.1161/01.CIR.0000159356.42064.48. PMID 15781732. 
  12. ^ a b Xu J, Jian B, Chu R, Lu Z, Li Q, Dunlop J, Rosenzweig-Lipson S, McGonigle P, Levy RJ, Liang B (December 2002). "Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells". Am. J. Pathol. 161 (6): 2209–18. PMID 12466135. PMC: 1850896. http://ajp.amjpathol.org/cgi/content/abstract/161/6/2209. 
  13. ^ Jacobs G, Kamerling I, de Kam M, et al. (Nov 2008). "Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron". J Psychopharmacol. (Oxford). doi:10.1177/0269881108094299. PMID 18719048. 

[edit] Further reading

  • den Boer JA, Westenberg HG (1990). "Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder". Psychiatry research 31 (3): 267–78. doi:10.1016/0165-1781(90)90096-N. PMID 2139731. 
  • Angst J, Woggon B, Schoepf J (1977). "The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study". Archiv für Psychiatrie und Nervenkrankheiten 224 (2): 175–86. PMID 336002. 
  • article at Psychology Today
Personal tools